SCHEMBL6449844

SCHEMBL6449844

CCOc1cccc(-c2nc(-c3ncccc3C)n[nH]2)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 4/20 0.44
PLAU P00749 4/20 0.44
F10 P00742 3/20 0.44
F2 P00734 2/20 0.44
PLAT P00750 2/20 0.44
PDE5A O76074 1/20 0.40
S1PR1 P21453 1/20 0.38
GRM5 P41594 2/20 0.38
ADORA2A P29274 2/20 0.37
ADORA1 P30542 1/20 0.37
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.35
ALOX12 P18054 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6448709 0.89 KDM4E (0.44) PLGPLAUF10F2PLAT
SCHEMBL6454710 0.88 PLG (0.43) PLGPLAUF10F2PLAT
SCHEMBL6452888 0.86 PLG (0.48) PLGPLAUF10F2PLAT
SCHEMBL6460914 0.85 PLG (0.41) PLGPLAUF10F2PLAT
SCHEMBL6454173 0.83 S1PR1 (0.47) PLGPLAUF10F2PLAT
SCHEMBL6448775 0.82 SMN1; SMN2 (0.53) PLGPLAUF10F2PLAT
SCHEMBL6449994 0.81 NPSR1 (0.50) S1PR1ALDH1A1GAAKDM4EMAPT
SCHEMBL6451388 0.80 PLG (0.45) PLGPLAUF10F2PLAT
SCHEMBL6450012 0.78 ADORA2A (0.57) PDE5AADORA2AGAAKDM4EMAPT
SCHEMBL6448821 0.78 PLG (0.44) PLGPLAUF10F2PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC PLG 4331/4885PLAU 3775/4885F10 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.